Polymer Therapeutics

Evenepoel P, Selgas R, Caputo F, Foggensteiner L, Heaf JG, Ortiz A, Kelly A, Chasan-Taber S, Duggal A, Fan S. 2009. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. Nephro Dial Transplant 24(1):278-85.

Avila LZ, Gianolio DA, Konowicz PA, Philbrook M, Santos MR, Miller RJ. 2008. Drug delivery and medical applications of chemically modified hyaluronan. In: Garg HG, Cowman MK, Hales CA, editors. Carbohydrate Chemistry, Biology and Medical Applications. Oxford, U.K.: Elsevier. p 333-57.

Ferreira A, Frazão JM, Monier-Faugere M-C, Gil C, Galvao J, Oliveira C, Baldaia J, Rodrigues I, Santos C, Ribeiro S, Hoenger RM, Duggal A, Malluche HH. 2008. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Amer Soc of Nephrology 19(2):405-12.

Hinkson PL, Dinardo C, DeCiero D, Klinger JD, Barker RHJ. 2008. Tolevamer, an anionic polymer, neutralizes toxins produced by the BI/027 strains of Clostridium difficile. Antimicrob Agents & Chemotherapy 52 (6):2190-5.

Ketteler M, Rix M, Fan S, Pritchard N, Oestergaard O, Chasan-Taber S, Heaton J, Duggal A, Kalra PA. 2008. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Amer Soc of Nephrol 3(4):1125-30.

Peppe J, Porzio A, Davidson DM. 2008. A new formulation of tolevamer, a novel nonantibiotic polymer, is safe and well-tolerated in healthy volunteers: a randomized phase I trial. Br J Clin Pharmacol.

Sampath TK, Simic P, Moreno S, Bukanov N, Draca N, Kufner V, Tikvica A, Blair A, Semenski D, Brncic M, Burke SK, Vukicevic S. 2008. Sevelamer restores bone volume and improves bone microarchitecture and strength in aged ovariectomized rats. Endocrinology 149(12):6092-102.

Taylor MJ, Elgazzar HA, Chaplin S, Goldsmith D, Molony DA. 2008. An economic evaluation of sevelamer in patients new to dialysis. Curr Med Res and Opin 24(2):601-608.

Cyr JE, Pearson DA, Wilson DM, Nelson CA, Guaraldi M, Azure MT, Lister-James J, Dinkelborg LM, Dean RT. 2007. Somatostatin receptor-binding peptides suitable for tumor radiotherapy with Re-188 or Re-186. Chemistry and initial biological studies. J Med Chem 50(6):1354-64.

Delmez J, Block G, Robertson J, Chasan-Taber S, Blair A, Dillon M, Bleyer AJ. 2007. A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clinical Nephrology 68(6):386-91.

Dhal PK, Huval CC, Holmes-Farley SR. 2007. Biologically active polymeric sequestrants: Design, synthesis, and therapeutic applications. Pure & Applied Chem 79(9):1521-30.

Fife C, Mader JT, Stone J, Brill L, Satterfield K, Norfleet A, Zwernemann A, Ryaby JT, Carney DH. 2007. Thrombin peptide Chrysalin® stimulates healing of diabetic foot ulcers in a placebo-controlled phase I/II study. Wound Repair & Regeneration 15(1):23-34.

.O'Brien JA, Lahue BJ, Caro JJ, Davidson DM. 2007. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: Clinical and economic consequences. Infection Control and Hospital Epidemiology 28(11):1219-27.

Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, Ling BN, Chasan-Taber S, Dillon MA, Blair AT, Burke SK. 2007. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Intl 72(9):1130-7.

Barker RHJ, Dagher R, Davidson DM, Marquis JK. 2006. Review article: Tolevamer, a novel toxin-binding polymer: overview of preclinical pharmacology and physicochemical properties. Aliment Pharmacol Ther 24:1525-1534.

Duggal A, Hanus M, Zhorov E, Dagher R, Plone MA, Goldberg J, Burke SK. 2006. Novel dosage forms and regimens for sevelamer-based phosphate binders. J Ren Nutr 16:248-252.

Hanus M, Zhorov E. 2006. Bile acid salt binding with colesevelam HCl is not affected by suspension in common beverages. J Pharm Sci 95:2751-2759.

Marquis JK, Dagher R, Baker BA, Jones MR. 2006. Colesevelam hydrochloride does not cause maternal or fetal toxicity in rats and rabbits. Reprod Tox 21:197-207.

Donovan JM, Von Bergmann K, Setchell KD, Isaacsohn J, Pappu AS, Illingworth DR, Olson T, Burke SK. 2005. Effects of colesevelam HC1 on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. Dig Dis Sci 50:1232-1238.

Ferramosca E, Burke S, Chasan-Taber S, Ratti C, Chertow GM, Raggi P. 2005. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J 149:820-825.

Garg JP, Chasan-Taber S, Blair A, Plone M, Bommer J, Raggi P, Chertow GM. 2005. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. Arthritis Rheum 52:290-295.

Polomoscanik SC, Cannon CP, Neenan TX, Holmes-Farley SR, Mandeville WH, Dhal PK. 2005. Hydroxamic acid-containing hydrogels for nonabsorbed iron chelation therapy: synthesis, characterization, and biological evaluation. Biomacromole 6:2946-2953.

Braunlin W, Xu Q, Hook P, Fitzpatrick R, Klinger JD, Burrier R, Kurtz CB. 2004. Toxin binding of tolevamer, a polyanionic drug that protects against antibiotic-associated diarrhea. Biophys J 87:534-539.

Burke SK. 2004. Arterial calcification in chronic kidney disease. Semin Nephrol 24:403-407.

Huval CC, Chen X, Holmes-Farley SR, Mandeville WH, Polomoscanik SC, Sacchiero RJ, Dhal PK. 2004. Molecularly imprinted bile acid sequestrants: synthesis and biological studies. Mat Res Soc Sym Proc 787:85-90.

Huval CC, Holmes-Farley SR, Mandeville WH, Sacchiero R, Dhal PK. 2004. Syntheses of hydrophobically modified cationic hydrogels by copolymerization of alkyl substituted diallylamine monomers and their use as bile acid sequestrants. Eu Polymer J 40:693-701.

Huval CC, Holmes-Farley SR, Mandeville WH, Petersen JS, Sacchiero RJ, Maloney C, Dhal PK. 2004. Ammonium and guanidinium functionalized hydrogels as bile acid sequestrants: Synthesis, characterization, and biological properties. J Macromole Sci Pure & App Chem A41:231-244.

Marquis JK, Dagher R, Jones M. 2004. Dietary administration of colesevelam hydrochloride does not affect fertility or reproductive performance in rats. Int J Toxicol 23:357-367.

Swearingen RA, Zhorov E, Cohen A, Sybertz T, Barry EF. 2004. Determination of the binding parameter constants of Renagel capsules and tablets at pH 7 by high performance capillary electrophoresis. J Pharma & Biomed Anal 35:753-760.

Zhang B, Krull IS, Cohen A, Smisek DL, Kloss A, Wang B, Bourque AJ. 2004. Separation of quaternary ammonium diastereomeric oligomers by capillary electrophoresis. J Chromatogr A 1034:213-220.

Burke SK, Dillon MA, Hemken DE, Rezabek MS, Balwit JM. 2003. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients. Adv in Renal Replac Ther 10:133-145.

Chertow GM, Raggi P, McCarthy JT, Schulman G, Silberzweig J, Kuhlik A, Goodman WG, Boulay A, Burke SK, Toto RD. 2003. The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. Am J Nephrol 23:307-314.

Cozzolino M, Staniforth ME, Liapis H, Finch J, Burke SK, Dusso AS, Slatopolsky E. 2003. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int 64:1653-1661.

Katsumata K, Kusano K, Hirata M, Tsunemi K, Nagano N, Burke SK, Fukushima N. 2003. Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats. Kidney Int 64:441-450.

Nagano N, Miyata S, Obana S, Kobayashi N, Fukushima N, Burke SK, Wada M. 2003. Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency. Nephrol Dial Transplant 18:2014-2023.

Amin N. 2002. The impact of improved phosphorus control: Use of sevelamer hydrochloride in patients with chronic renal failure. Nephrol Dial Transplant 17:340-345.

Braunlin W, Zhorov E, Guo A, Apruzzese W, Xu Q, Hook P, Smisek DL, Mandeville WH, Holmes-Farley SR. 2002. Bile acid binding to sevelamer HCl. Kidney Int 62:611-619.

Chertow GM, Burke SK, Raggi P. 2002. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245-252.

Cozzolino M, Dusso AS, Liapis H, Finch J, Lu Y, Burke SK, Slatopolsky E. 2002. The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats. J Am Soc Nephrol 13:2299-2308.

Donovan JM, Kisicki JC, Stiles MR, Tracewell WG, Burke SK. 2002. Effect of colesevelam on lovastatin pharmacokinetics. Ann Pharmacother 36:392-397.

Plone MA, Petersen JS, Rosenbaum DP, Burke SK. 2002. Sevelamer, a phosphate-binding polymer, is a non-absorbed compound. Clin Pharmacokinet 41:517-523.

Swearingen RA, Chen X, Petersen JS, Riley KS, Wang D, Zhorov E. 2002. Determination of the binding parameter constants of Renagel capsules and tablets utilizing the Langmuir approximation at various pH by ion chromatography. J Pharm Biomed Anal 29:195-201.